Regulation of Medical Devices Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation.

Slides:



Advertisements
Similar presentations
1 Testing in the Open Market Testing in the Open Market AAAS Colloquium on Personalized Medicine: Planning for the Future June 2, 2009 Courtney C. Harper,
Advertisements

0 - 0.
Addition Facts
Investigational Device Exemption (IDE) Overview for IRBs
Regulatory Pathway for Platform Technologies
Entering the US Market: Medical Devices
Investigational Device Exemptions 21 CFR Part 812
Device World: The Basics SR and NSR Determinations Expanded Access Susie Hoffman University of Virginia Margaret Foster Riley, J.D. University of Virginia,
Investigational Device Exemptions (IDE) CFR Title 21, Part 812
IRB Process & Medical Devices
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Overview of FDA Device Regulations
Barbara Gibson, MS, RN, CCRC, CIP, CHRC Regulatory Affairs Officer Vanderbilt Human Research Protection Program.
Dietary Supplements Foods or Drugs?
Replacement Reagent Policy Update
Carole C. Carey, BSEE, M.Engineering Director, International Staff
Addition 1’s to 20.
Test B, 100 Subtraction Facts
Week 1.
"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
FDA Regulated Research:
Humanitarian Device Exemptions (HDE) 101 Elizabeth Hillebrenner, MSE Biomedical Engineer IDE and HDE Program Staff Center for Devices and Radiological.
IRB Review of Device Research and Other Clinical Uses of Devices
Strengthening the Medical Device Clinical Trial Enterprise
510k Submission Overview Myraqa, Inc. August 22, 2012.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
Clinical Trials Medical Interventions
Medical Device Submissions
IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.
CUMC IRB Investigator Meeting Special IND/IDE Considerations: Emergency Use of Investigational Product Compassionate Use & Emergency Research July 21,
Special Topics in IND Regulation
Medical Devices Approval Process
Investigational New Drug Application 21 CFR Part 312 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Weaving regulations into sound value analysis processes Barbara Strain, MA, SM(ASCP) Director Value Management University of Virginia Health System.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
Device Research Presented by Marian Serge, R.N.. Goals Identify devices Recognize difference between significant risk (SR) and non- significant risk (NSR)
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
Medical Devices IRB Determination IRB Member Continuing Education.
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Welcome New IRB Members! Today we will discuss: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.
Utah Life Science Summit Nov Phil Triolo, PhD RAC President, Phil Triolo and Associates LC.
Regulatory Decision Making D. Kathleen Wright, Reviewer Division of Microbiology Office of In Vitro Diagnostic Device Evaluation & Safety ( OIVD ) Food.
Investigational Devices and Humanitarian Use Devices June 2007.
Regulatory requirements: children, assent, and consent waivers and waiver of documentation Bob Craig, 2007.
Welcome New IRB Member! This brief presentation covers: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.
HUD and Emergent Use Walter Kraft. Device Classification Significant risk – Often involve an invasive procedure for implantation or use – Requires IDE.
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
Radiology Advisory Panel Meeting Radiology Advisory Panel Meeting Computer-Assisted Detection (CADe) Devices Joyce M. Whang Deputy Division Director Radiological.
EXCEPTION FROM INFORMED CONSENT IN CPR DEVICE TRIALS: PROTECTION OF PATIENTS’ RIGHTS Circulatory System Devices Panel Meeting September 21, 2004 Elisa.
PD233: Design of Biomedical Devices and Systems (Lecture 2) Dr. Manish Arora CPDM, IISc Course Website:
The CRT of EFS Where We’ve Been and Where We’re Going
Use of Postmarket Data to Support Premarket Approvals
GCP AND MEDICAL DEVICES
What Are the FDA Requirements for Submitting an IDE?
Division of Cardiovascular Devices
Premarket Notification 510(k) process
Andrew Farb, MD and Dorothy Abel, BSBME
FDA’s IDE Decisions and Communications
FDA Perspective on Cardiovascular Device Development
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Bozeman Health Clinical Research
Device Review Decision Tree Version Date: 4/28/15 This decision tree to be used for studies involving research on a device ( approved or unapproved)
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
FDA Medical Device Approval Pathways
Opening an IND: Investigator Perspective
Presentation transcript:

Regulation of Medical Devices Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Food and Drug Administration RHAIR Society for Academic Emergency Medicine Boston, Massachusetts May 31, 2003

2 Outline Outline Who we are Who we are Device types Device types Paths to market Paths to market Temperature control devices Temperature control devices Clinical study regulation Clinical study regulation

3 FDA CVMCFSCANCDRH OSTOSMOSBODE DAGID DCD *DGRND DOED DRARD OHIPOCOIVD CBERCDER Who We Are

4 Device Examples Neuroembolization devices Neuroembolization devices Deep brain stimulators Deep brain stimulators Neurodiagnostic devices (EEG, EMG) Neurodiagnostic devices (EEG, EMG) Neurosurgical shunts Neurosurgical shunts Muscle stimulators Muscle stimulators Neurovascular stents Neurovascular stents

5 Regulatory Review: Pathways to Market Regulatory Review: Pathways to Market Premarket Notification 510(k) Premarket Notification 510(k) Premarket Approval Application (PMA) Premarket Approval Application (PMA) Product Development Protocol (PDP) Product Development Protocol (PDP) Humanitarian Device Exemption (HDE) Humanitarian Device Exemption (HDE) De Novo Classification De Novo Classification

6 Premarket Notification 510(k) Substantial Equivalence Substantial Equivalence Predicate Device (legally marketed, not subject to PMA) Predicate Device (legally marketed, not subject to PMA) Comparison Comparison – same intended use and – same technological characteristics or – different technological characteristics and – as safe and effective as predicate

7 Premarket Application (PMA) …reasonable assurance of safety and effectiveness…

8 Regulatory Path Examples

9 Hydrocephalus Shunts 510(k) (substantial equivalence) 510(k) (substantial equivalence) Comparison to predicate Comparison to predicate Standards: Standards: – ASTM F647 – ISO 7197 Materials/biocompatibility Materials/biocompatibility For new/unusual designs, may need a For new/unusual designs, may need a clinical study for – Infection – Revision/causes – Failures/failure modes

10 Intracranial Neurovascular Stents Class III (PMA/HDE/PDP) Class III (PMA/HDE/PDP) 2 HDEs approved 2 HDEs approved

11 Deep Brain Stimulation Class III Class III PMA approval for essential tremor and Parkinsons disease symptoms PMA approval for essential tremor and Parkinsons disease symptoms

12 Clinical Study Regulation Clinical Study Regulation FFD&C Act gives FDA the authority to regulate investigational devices: To encourage the discovery and development of new devices To encourage the discovery and development of new devices Maintain optimum freedom for scientific investigations Maintain optimum freedom for scientific investigations

13 Section 520(g) of the Act Requires IRB approval for all clinical investigations Requires IRB approval for all clinical investigations Requires informed consent from all subjects unless emergency use Requires informed consent from all subjects unless emergency use

14 IDE Regulation (Part 812) Allows an unapproved device to be shipped for clinical evaluation: Identifies sections of the Act from which IDEs are exempt Identifies sections of the Act from which IDEs are exempt Identifies exempted investigations (e.g. cleared devices, IVDs) Identifies exempted investigations (e.g. cleared devices, IVDs) Defines SR and NSR investigations Defines SR and NSR investigations

15 Significant Risk (SR) Study Presents a potential serious risk to the health, safety, and welfare of a subject and is: Presents a potential serious risk to the health, safety, and welfare of a subject and is: – an implant; or – life supporting or sustaining; or – of substantial importance in diagnosing, curing, mitigating, or treating disease or preventing impairment of human health FDA approval required FDA approval required

16 Non-significant Risk Studies FDA approval not needed FDA approval not needed Examples: Examples: – MRI < 4 Tesla – Urologic catheters – Low level biostimulation lasers – Laparoscopes NSR devices can be SR studies NSR devices can be SR studies

17 Informed Consent: Emergency Use Must be reviewed and approved by the IRB and the FDA prior to use Must be reviewed and approved by the IRB and the FDA prior to use May be waived when there is a life- threatening situation May be waived when there is a life- threatening situation – the subject cannot communicate – time is not sufficient – no available alternative – two physicians certify in writing

18 Informed Consent: Emergency Research Certain studies may not require informed consent when IRB agrees that Certain studies may not require informed consent when IRB agrees that – there is a life-threatening situation and current treatments are unsatisfactory treatments are unsatisfactory – no time – cant identify subjects prospectively – community consultation – public disclosure

19 When Are Clinical Data Needed? To support: PMA, PDP or HDE (almost always) PMA, PDP or HDE (almost always) 510(k) (<10%) 510(k) (<10%) New indication for an approved device (e.g., BPH for a urologic laser) New indication for an approved device (e.g., BPH for a urologic laser) Significant change to device, especially Class III devices Significant change to device, especially Class III devices

20 Types of Studies Types of Studies Sponsor-investigator Sponsor-investigator Manufacturer-sponsored Manufacturer-sponsored –Feasibility –Pivotal, including sites outside the US –Post-approval

21 Feasibility Trial Feasibility Trial Answer design-related questions that cannot be addressed by bench/animal testing Answer design-related questions that cannot be addressed by bench/animal testing Modify device design &/or instructions for use Modify device design &/or instructions for use Preliminary safety data Preliminary safety data No control No control Limited # pts/limited follow-up Limited # pts/limited follow-up

22 Pivotal Trial Pivotal Trial Final design, indication for use, and protocol Final design, indication for use, and protocol Controlled Controlled Masked, if possible Masked, if possible Primary/secondary endpoints Primary/secondary endpoints Develop information for labeling Develop information for labeling Statistical validity to show S & E Statistical validity to show S & E

23 Post-Approval May be required for PMA approval May be required for PMA approval Designed to address specific question Designed to address specific question # of patients and duration specified by FDA # of patients and duration specified by FDA

24 Cooling Devices: Clinical Study Questions How soon? How soon? How cold? How cold? How fast? How fast? How long? How long? How measured? How measured? Speed of rewarming? Speed of rewarming? Other treatments provided? Other treatments provided? Local versus systemic? Local versus systemic?

25 Temperature Control Devices Tool? Tool? Treatment? Treatment?

26 Temperature Control Devices Cooling Blankets Cooling Blankets Endovascular Devices Endovascular Devices

27